Posters

Effect of diquafosol 3% ophthalmic solution on ocular surface and corneal aberration after cataract surgery

Poster Details

First Author: K.Sangmyung SOUTH KOREA

Co Author(s):    S. Park   Y. Ji   H. Lee   K. Seo   E. Kim   T. Kim     

Abstract Details

Purpose:

To evaluate the effect of diquafosol 3% ophthalmic solution on tear film parameters and ocular aberration after cataract surgery in eyes with mild and moderate dry eye syndrome.

Setting:

The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea

Methods:

Patients who underwent cataract surgery were divided into two groups. Patients in group I (19 eyes) were treated with diquafosol 3% ophthalmic solution from 1 week before surgery to 3 months after surgery. Patients in group II (22 eyes) underwent cataract surgery without application of diquafosol 3% ophthalmic solution. Tear film break-up time (BUT), Ocular surface disease index (OSDI), Oxford staining score, Schirmer’s test I, and corneal aberrations were evaluated before and 1, 3 months after cataract surgery.

Results:

In group I, BUT, OSDI, and Oxford staining score were significantly improved at 1 month (P=0.002, 0.005, 0.005) and 3 months (P=0.004, 0.005, 0.020) after surgery compared with preoperative value. However, tear production decreased significantly at 3 months after surgery (P=0.011). Regarding the BUT, OSDI, and Oxford staining score, group 1 showed the tendency to demonstrate better results after cataract surgery. Especially. OSDI in group I was significantly lower than that in group II at 1 month and 3 months after surgery (P=0.013 and P=0.035). In group 1, root mean square higher-order aberration, Trefoil 6, and Trefoil 10 decreased at 3 months after surgery. Other parameters for ocular aberration showed comparable results between the two groups.

Conclusions:

Use of Diquafosol 3% ophthalmic solution before and after cataract surgery can be effective for improving dry eye syndrome and corneal aberration after cataract surgery.

Financial Disclosure:

NONE